neostigmine has been researched along with Bronchial Spasm in 7 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Bronchial Spasm: Spasmodic contraction of the smooth muscle of the bronchi.
Excerpt | Relevance | Reference |
---|---|---|
"Sugammadex and neostigmine given to reverse residual neuromuscular blockade can cause side effects including bradycardia, anaphylaxis, bronchospasm, and even cardiac arrest." | 4.12 | Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects. ( Chahar, P; Chhabada, S; Khanna, S; Li, K; Maheshwari, K; Ruetzler, K; Schmidt, MT; Sessler, DI; Turan, A; Yang, D, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (57.14) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Ruetzler, K | 1 |
Li, K | 1 |
Chhabada, S | 1 |
Maheshwari, K | 1 |
Chahar, P | 1 |
Khanna, S | 1 |
Schmidt, MT | 1 |
Yang, D | 1 |
Turan, A | 1 |
Sessler, DI | 1 |
USPENSKAIA, EP | 2 |
Hazizaj, A | 1 |
Hatija, A | 1 |
Sun, KO | 1 |
Pratt, CI | 1 |
Droszcz, W | 1 |
Bogoslawski, RW | 1 |
Belik, IE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Patients Undergoing Laparoscopic Gastric Bypass Surgery[NCT01748643] | Phase 4 | 60 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Measured from the time of first skin incision to completion of skin closure. (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h
Intervention | minutes (Mean) |
---|---|
Deep Neuromuscular Blockade, Reversal With Sugammadex | 61.3 |
Normal Neuromuscular Blockade, Reversal With Neostigmine | 70.6 |
Forced expiratory volume in 1 second is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))
Intervention | percent change from baseline (Mean) |
---|---|
Deep Neuromuscular Blockade, Reversal With Sugammadex | 45.2 |
Normal Neuromuscular Blockade, Reversal With Neostigmine | 48.8 |
Forced vital capacity is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))
Intervention | percent change from baseline (Mean) |
---|---|
Deep Neuromuscular Blockade, Reversal With Sugammadex | 51.9 |
Normal Neuromuscular Blockade, Reversal With Neostigmine | 49.0 |
The number of intra-abdominal pressure rises > 18cmH2O detected by the intra-abdominal CO2 insufflator. (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h
Intervention | number of intra-abdominal pressure rises (Mean) |
---|---|
Deep Neuromuscular Blockade, Reversal With Sugammadex | 0.2 |
Normal Neuromuscular Blockade, Reversal With Neostigmine | 0.3 |
Peak expiratory flow is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))
Intervention | percent change from baseline (Mean) |
---|---|
Deep Neuromuscular Blockade, Reversal With Sugammadex | 51.3 |
Normal Neuromuscular Blockade, Reversal With Neostigmine | 51.5 |
"At the end of surgery, the view on the operating field will be graded by the surgeon using a 5-point rating scale:~Extremely poor~Poor~Acceptable~Good~Optimal" (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h
Intervention | units on a scale (Mean) |
---|---|
Deep Neuromuscular Blockade, Reversal With Sugammadex | 4.2 |
Normal Neuromuscular Blockade, Reversal With Neostigmine | 3.9 |
7 other studies available for neostigmine and Bronchial Spasm
Article | Year |
---|---|
Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects.
Topics: Anaphylaxis; Bradycardia; Bronchial Spasm; Child; Cohort Studies; Delayed Emergence from Anesthesia; | 2022 |
[Experimental therapy of proserine bronchospasm].
Topics: Bronchi; Bronchial Diseases; Bronchial Spasm; Disease; Neostigmine; Parasympathomimetics; Therapies, | 1956 |
[Experimental therapy of proserine bronchospasm].
Topics: Bronchi; Bronchial Diseases; Bronchial Spasm; Disease; Neostigmine; Parasympathomimetics; Therapies, | 1956 |
[Experimental therapy of proserine bronchospasm].
Topics: Bronchi; Bronchial Diseases; Bronchial Spasm; Disease; Neostigmine; Parasympathomimetics; Therapies, | 1956 |
[Experimental therapy of proserine bronchospasm].
Topics: Bronchi; Bronchial Diseases; Bronchial Spasm; Disease; Neostigmine; Parasympathomimetics; Therapies, | 1956 |
Bronchospasm caused by neostigmine.
Topics: Adult; Anesthesia, General; Asthma; Bronchial Spasm; Cholinesterase Inhibitors; Humans; Male; Nasal | 2006 |
Bronchospasm after esmolol and neostigmine.
Topics: Adrenergic beta-Antagonists; Appendectomy; Bronchial Spasm; Humans; Intraoperative Complications; Ma | 1993 |
Bronchospasm after neostigmine.
Topics: Bronchial Spasm; Humans; Intraoperative Complications; Neostigmine | 1988 |
Investigations on the role of acetylcholine esterase in hypersensitivity states. II. Prostigmine provocation test in patients with bronchial asthma.
Topics: Acetylcholinesterase; Adult; Asthma; Bronchial Spasm; Humans; Middle Aged; Neostigmine; Respiratory | 1974 |
[Experimental basis of surgical intervention in patients with bronchial asthma].
Topics: Adolescent; Adult; Aged; Animals; Asthma; Bronchial Spasm; Carotid Sinus; Child; Denervation; Dogs; | 1967 |